Effect of gamma-aminobutyric acid treatment on plasma substance P and calcitonin gene-related peptide levels in children with asthma.
- Author:
Chuan-Wei XU
1
;
Shan-Chun GUO
;
Zhen-Wen ZHENG
;
Qing-Yuan WANG
Author Information
- Publication Type:Journal Article
- MeSH: Asthma; blood; drug therapy; Calcitonin Gene-Related Peptide; blood; Child; Child, Preschool; Female; Humans; Male; Substance P; blood; gamma-Aminobutyric Acid; pharmacology; therapeutic use
- From: Chinese Journal of Contemporary Pediatrics 2013;15(2):102-104
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the changes in plasma substance P (SP) and calcitonin gene-related peptide (CGRP) levels in children with acute asthma before and after gamma-aminobutyric acid (GABA) treatment.
METHODSSeventy-five children with asthma were randomly assigned to GABA treatment (n=36) and control groups (n=39). Both groups were given conventional treatment for asthma. Besides the conventional treatment, the treatment group was administered with oral GABA (25-30 mg/kg•d). Plasma content of SP and CGRP was measured using ELISA before treatment and after remission.
RESULTSThere were no significant differences in plasma content of SP and CGRP between the GABA treatment and control groups (P>0.05) before treatment. Plasma content of SP and CGRP in the GABA treatment group was significantly lower than the control group (SP: 57±15 pg/mL vs 127±12 pg/mL; CGRP: 23±10 pg/mL vs 42±8 pg/mL) after remission (P<0.01). Plasma content of SP and CGRP after remission was significantly lower than before treatment (P<0.01) in both groups. There was a significantly positive correlation between plasma SP and CGRP content in asthmatic children (r=0.792, P<0.01).
CONCLUSIONSGABA can significantly decrease plasma levels of SP and CGRP in children suffering from acute asthma.